Related Experiment Videos
Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis
Takaya Abe1, Kazuhiro Uchita, Hikari Orita
1Center of Blood Purification Therapy, Wakayama Medical University, Wakayama, Japan. takayabe@hitmark.com
Background:
beta2-microglobulin (beta2-m) is considered a major pathogenic factor in dialysis-related amyloidosis (DRA), often seen in long-term dialysis patients. No effective therapy for this severely debilitating disease is currently available. Lixelle, an adsorption column, has been developed for the elimination of beta2-m; the efficacy of this column has been evaluated in this study.
Methods:
Seventeen hemodialysis patients with DRA were first treated with high-flux dialysis for a minimum of 1 year. This was followed by 1-year treatment with Lixelle column connected in series to the high-flux dialyzer. Treatments were used three times a week for both phases of this study. During the study period, beta2-m, pinch strength, motor terminal latency, and activities of daily living were evaluated.
Results:
After 1-year treatment with high-flux dialysis the beta2-m level remained unchanged; however, after 1-year treatment with the addition of the Lixelle column, beta2-m level decreased significantly from 34.5 +/- 8.4 mg/L to 28.8 +/- 7.3 mg/L (P < 0.05). After 1 year of Lixelle column use, the pinch strength increased from 6.8 +/- 4.7 pounds to 9.1 +/- 5.5 pounds (P < 0.01), and the median motor terminal latency was significantly reduced from 5.1 +/- 1.0 mseconds to 4.5 +/- 1.1 mseconds. A significant improvement was also observed in the activities of daily living score of the upper extremities.
Conclusion:
These results suggest that the addition of Lixelle to the high-flux dialyzer is associated with a significant clinical improvement in DRA patients.
Insights
Lixelle adsorption columns significantly reduced beta2-microglobulin levels and improved clinical symptoms in dialysis-related amyloidosis patients. This novel therapy offers hope for managing this debilitating condition.
Area of Science:
- Nephrology
- Biomedical Engineering
- Clinical Medicine
Background:
- Dialysis-related amyloidosis (DRA) is a debilitating condition in long-term dialysis patients, primarily caused by beta2-microglobulin (beta2-m).
- Currently, no effective therapies exist for DRA, highlighting the need for innovative treatment strategies.
- Lixelle, an adsorption column designed to remove beta2-m, has been developed and its efficacy investigated.
Purpose of the Study:
- To evaluate the efficacy of the Lixelle adsorption column in reducing beta2-microglobulin levels.
- To assess the clinical impact of Lixelle treatment on patients with dialysis-related amyloidosis.
- To determine if Lixelle improves functional outcomes in DRA patients.
Main Methods:
- Seventeen patients with DRA underwent 1 year of high-flux dialysis followed by 1 year of high-flux dialysis with an in-series Lixelle column.
- Treatments were administered three times weekly.
- Evaluated parameters included beta2-m levels, pinch strength, motor terminal latency, and activities of daily living.
Main Results:
- High-flux dialysis alone did not alter beta2-m levels.
- The addition of the Lixelle column significantly reduced beta2-m levels from 34.5 +/- 8.4 mg/L to 28.8 +/- 7.3 mg/L (P < 0.05).
- Significant improvements were observed in pinch strength (P < 0.01), motor terminal latency (P < 0.01), and activities of daily living.
Conclusions:
- The addition of Lixelle to high-flux dialysis is a promising therapeutic approach for DRA.
- Lixelle treatment leads to significant clinical improvements in patients suffering from dialysis-related amyloidosis.
- This study suggests Lixelle can effectively manage beta2-m accumulation and its associated complications.